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 ABSTRACT 
 The objective of this study was to develop a decision 
tree to evaluate the economic impact of different dura-
tions of intramammary treatment for the first case of 
mild or moderate clinical mastitis (CM) occurring in 
early lactation with various scenarios of pathogen dis-
tributions and use of on-farm culture. The tree included 
2 decision and 3 probability events. The first decision 
evaluated use of on-farm culture (OFC; 2 programs 
using OFC and 1 not using OFC) and the second deci-
sion evaluated treatment strategies (no intramammary 
antimicrobials or antimicrobials administered for 2, 5, 
or 8 d). The tree included probabilities for the distri-
bution of etiologies (gram-positive, gram-negative, or 
no growth), bacteriological cure, and recurrence. The 
economic consequences of mastitis included costs of 
diagnosis and initial treatment, additional treatments, 
labor, discarded milk, milk production losses due to 
clinical and subclinical mastitis, culling, and transmis-
sion of infection to other cows (only for CM caused 
by Staphylococcus aureus). Pathogen-specific estimates 
for bacteriological cure and milk losses were used. The 
economically optimal path for several scenarios was de-
termined by comparison of expected monetary values. 
For most scenarios, the optimal economic strategy was 
to treat CM caused by gram-positive pathogens for 2 
d and to avoid antimicrobials for CM cases caused by 
gram-negative pathogens or when no pathogen was 
recovered. Use of extended intramammary antimicro-
bial therapy (5 or 8 d) resulted in the least expected 
monetary values. 
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 INTRODUCTION 
 Mastitis is a disease of the mammary gland caused by 
bacterial infection and is the most common and costly 
health disorder of dairy cows (Ruegg, 2003). Mastitis 
has a negative economic impact on dairy farms in terms 
of discarded milk, lost production, reduced milk qual-
ity, and treatment costs (Seegers et al., 2003; Gröhn 
et al., 2004). Although antimicrobial therapy is not 
necessary for successful treatment of clinical mastitis 
(CM) caused by all pathogens, most cows with cases 
of CM are treated with intramammary antimicrobials 
(Pol and Ruegg, 2007; Hill et al., 2009). 
 Clinical mastitis is often classified according to se-
verity as mild (milk looks abnormal), moderate (milk 
looks abnormal and the udder or quarter is swollen), 
or severe (the cow exhibits systemic signs). Although 
immediate action using systemic treatment is gener-
ally recommended for severe cases of CM, selective 
treatment based on the causative pathogen is often 
recommended for mild and moderate cases. On-farm 
culture (OFC) programs are one approach used to help 
farmers rapidly diagnose the pathogen responsible for 
CM (Neeser et al., 2006; Lago, 2009). On-farm culture 
programs generally use selective media to differentiate 
among gram-positive or gram-negative pathogens and 
apply treatments according to etiology (Neeser et al., 
2006; Lago, 2009). Using OFC, microbiological results 
can be obtained within 24 h, as opposed to waiting at 
least 48 h to receive results from a diagnostic laboratory. 
Short-term clinical and bacteriological outcomes have 
been reported for cows that received selective treat-
ment of CM based on OFC results (Neeser et al., 2006; 
Lago, 2009). However, economic outcomes of selective 
treatment based on OFC have not been estimated. 
 The evaluation of treatment strategies for CM can 
be at the cow level and is based on biological and eco-
nomic factors. Biological outcomes from clinical trials 
using various treatments for CM have been described 
(Roberson et al., 2004; Hoe and Ruegg, 2005; Suojala 
et al., 2010) but the economic impact of mastitis treat-
ment protocols has received less attention. In recent 
years, the use of extended-duration therapy has been 
recommended and some studies support the concept 
that extended therapy significantly increases treatment 
efficacy for some mastitis pathogens (Gillespie et al., 
2002; Oliver et al., 2003, 2004a,b; Deluyker et al., 2005). 
However, the economic impact of mastitis treatments 
that are administered for extended durations has not 
been evaluated. 
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Decision tree analyses have been successfully used 
to evaluate economic decision making for treatment 
of various diseases of dairy cows (Ruegg and Carpen-
ter, 1989; Berry et al., 2004; Dorshorst et al., 2006). 
Decision tree analysis is a graphical representation 
of decisions, probabilities, and events, displayed in a 
logical and time-sequenced manner (Berry et al., 2004). 
However, the use of decision tree analysis to evaluate 
the economic outcome of treatments used for mild and 
moderate cases of CM at the individual cow level has 
not been previously reported. The objective of this 
study was to develop a decision tree to evaluate the 
economic impact of different durations of intramam-
mary treatment for the first case of mild or moder-
ate clinical mastitis occurring in early lactation with 
various scenarios of pathogen distributions and use of 
on-farm culture.
MATERIALS AND METHODS
Overview of the Decision Tree Model
Decision tree analysis was performed using TreePlan 
(Decision Toolworks, San Francisco, CA). The analyses 
were determined at the cow level for both primiparous 
and multiparous cows that were experiencing a mild 
or moderate case of clinical mastitis in a single mam-
mary gland quarter. Cases were assumed to occur at 30 
DIM to simulate early lactation cases that would have 
the maximum potential effect on lactation and were 
the first case of CM occurring in the current lactation. 
Economic calculations were based on consequences of 
CM until the end of a 305-d lactation. Decisions were 
ordered to reflect the sequence of decisions made by 
dairy producers. Economic values and probabilities 
were derived from research literature and expert knowl-
edge (in a few instances where research data was not 
available).
The decision tree (Figure 1) was constructed us-
ing (1) Decision nodes (represented by squares) with 
branches that represented strategies to be investigated 
and that were controllable (e.g., use of various OFC 
programs and use of various treatment durations). Es-
timated costs were assigned to each decision branch. 
(2) Probability nodes (represented by circles) with 
branches that represented uncontrollable events (e.g., 
distribution of pathogens causing CM, probability of 
bacteriological cure and probability of recurrence). Es-
timated probabilities and costs were assigned to each 
probability branch and summed to 100%. (3) Terminal 
nodes (represented by triangles) which summed the 
partial cash flows along a unique path leading to each 
terminal node.
Decisions Evaluated
Use of OFC. After detection of CM, 3 initial deci-
sions were evaluated: (1) Use OFC and then wait 24 h 
before initiating treatment (OFCW). After detection 
of CM, an aseptic milk sample was collected for OFC. 
No treatment was initiated during the first 24 h but 
milk was discarded. After 24 h, treatment was initi-
ated based on results of OFC. (2) Use OFC but begin 
treatment before results were known (OFCT). After 
detection of CM, an aseptic milk sample was collected 
for OFC. Intramammary (IMM) antimicrobial treat-
ment was initiated immediately, but the treatment was 
adjusted based on results of OFC after 24 h. (3) Treat 
without OFC (NOOFC). Treatment was performed 
without diagnosis of causative pathogen.
Treatment Strategies. The secondary decision 
evaluated 4 treatment strategies (Figure 1). The 
strategies that included the use of IMM antimicrobial 
consisted of the same generic drug administered for dif-
ferent durations. Milk was assumed to be discarded for 
3 d after the final treatment. When the initial decision 
was OFCW or NOOFC the treatment decisions were 
(1) do not treat the cow with antimicrobials (NOT); 
(2) use IMM antimicrobial treatment for 2 d (2DT); 
(3) use IMM antimicrobial treatment for 5 d (5DT); 
or (4) use IMM antimicrobial treatment for 8 d (8DT). 
When the initial decision was OFCT, similar treatment 
decisions were used but in this case, because the IMM 
antimicrobial treatment had already been initiated, the 
options were to stop treatment (STOP) or to continue 
treatment for 1 (C1DT), 4 (C4DT), or 7 (C7DT) d. 
Treatment durations >2 d were considered extended-
duration treatments.
Probability Events
Distribution of Etiologies. The baseline distribu-
tion of pathogens (scenario A) was based on Pinzón-
Sánchez (2010) and represented the distribution of 
pathogens observed on typical large commercial dairy 
herds located in Wisconsin. Pathogens for scenario A 
were distributed as 2% Staphylococcus aureus, 19% en-
vironmental streptococci, 14% CNS, 24% Escherichia 
coli, 6% Klebsiella spp., and 35% no growth (Table 1). 
The underlying pathogen distributions were used to 
categorize the etiologies as gram-positive pathogens, 
gram-negative pathogens, or no growth (no pathogen 
recovered) to represent typical diagnoses used for OFC. 
Gram-positive pathogens included Staph. aureus, envi-
ronmental streptococci, and CNS; gram-negative patho-
gens included E. coli and Klebsiella spp. It was assumed 
that the diagnosis obtained by using OFC was 100% 
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Figure 1. Simplified structure of the decision tree. Decision nodes are represented by squares with branches that represent strategies. 
Probabilities nodes are represented by circles with branches that represent probability events. Terminal nodes are represented by triangles.
accurate even though Lago (2009) determined that 
OFC was approximately 80% accurate. It is unlikely 
that this assumption affected the results of this study 
because savings attributable to OFC are a result of no 
treatment administered to gram-negative or no-growth 
cases, and the error (20%) would have been equally 
distributed between gram-positive and gram-negative 
pathogens. For OFCW and OFCT, each decision node 
was followed by a probability node with 3 branches 
(gram-positive, gram-negative, or no growth; Figure 1); 
NOOFC was followed by a decision about treatment 
strategy (Figure 1). In this branch, the same distribu-
tion of pathogens was modeled but treatment was not 
based on diagnosis of pathogen.
Probability of Bacteriological Cure. Probabili-
ties of bacteriological cure (Table 2) were estimated 
based on previous research (Smith et al., 1985; Morin 
et al., 1998; Pyörälä and Pyörälä, 1998; Wilson et al., 
1999; Gillespie et al., 2002; Oliver et al., 2004b; Rober-
son et al., 2004; Deluyker et al., 2005; Hoe and Ruegg, 
2005; McDougall et al., 2007; Bradley and Green, 2009; 
Suojala et al., 2010; van den Borne et al., 2010). The 
probability of bacteriological cure was estimated for 
primiparous cows based on treatment strategy and 
etiology and it was assumed that the probability of 
bacteriological cure for multiparous cows was always 
5% less (Table 2). Because no differences in posttreat-
ment outcomes were reported by Lago (2009), the same 
probabilities of bacteriological cure were used for cows 
treated with antimicrobial immediately after detection 
of CM and those treated 24 h later. The probability of 
bacteriological cure was estimated by pathogen; thus, 
weighted averages based on the distribution of pathogens 
were calculated to determine the overall bacteriological 
cure for the categorical outcomes of gram-positive and 
gram-negative pathogens (Table 3).
Probability of Recurrence. The probability of 
experiencing recurrent cases of CM was estimated 
based on data collected from 4 commercial dairy herds 
and varied with the occurrence of bacteriological cure 
(Pinzón-Sánchez, 2010). For primiparous cows, the 
probability of recurrence was assumed to be 2% for 
cases that resulted in bacteriological cure or 25% for 
cases that experienced persistent infection (no bacte-
riological cure). For multiparous cows, the probability 
of recurrence was assumed to be 12% for cases that 
resulted in bacteriological cure or 35% for cows that 
experienced persistent infection. Recurrent cases were 
assumed to have the same etiology and same severity as 
the first case. All recurrences were assumed to receive 
5 d of treatment with a total milk discard of 8 d. The 
first recurrent case (second case of CM) was assumed to 
occur 30 d (60 DIM) after the occurrence of the initial 
CM case. For the first recurrent case, the probabilities 
of bacteriological cure and recurrence were the same 
as those assumed for the first case of CM. The second 
recurrence (third case of CM) was assumed to occur 30 
d (90 DIM) after the first recurrent case.
Economic Consequences of Mastitis
The economic consequences of mastitis included costs 
of diagnosis (OFC), treatment, labor, discarded milk, 
milk production losses due to clinical and subclinical 
mastitis, culling, and transmission of infection to other 
cows (only for CM caused by Staph. aureus). Milk pro-
duction losses included milk loss due to CM, discarded 
milk, and milk loss due to subclinical mastitis. To allo-
cate milk production losses after occurrence of CM (30 
to 305 DIM), the daily potential milk production of a 
cow (primiparous or multiparous cows) was calculated 
based on typical lactation curves for Wisconsin dairy 
cows (Cabrera, 2010). Total potential milk yield from 
30 to 305 DIM was estimated to be 9,670 kg and 11,188 
kg for primiparous and multiparous cows, respectively. 
The average US milk price between 2008 and 2009 
of $0.33/kg was used as the baseline (USDA, 2010). 
Thus, potential income from milk production for stud-
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Table 1. Distribution of pathogens for scenarios A (baseline), B (greater prevalence of Staphylococcus aureus), 
and C (greater prevalence of coliform organisms) 
Etiology of clinical  
mastitis (%)
Scenario
A 
(baseline scenario)
B 
(greater contagious)
C 
(greater coliforms)
Gram-positive 0.35 0.70 0.15
 Staph. aureus 0.02 0.40 0.01
 Environmental streptococci 0.19 0.24 0.10
 CNS 0.14 0.06 0.04
Gram-negative 0.30 0.15 0.70
 Escherichia coli 0.24 0.10 0.60
 Klebsiella spp. 0.06 0.05 0.10
No growth 0.35 0.15 0.15
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Table 2. Estimated probabilities of bacteriological cure by pathogen and duration of intramammary treatment used for treatment of clinical mastitis occurring in primiparous and 
multiparous cows 
Etiology of clinical mastitis
Treatment  
duration (d)
Bacteriological cure (%)
SourcePrimiparous Multiparous 
Staphylococcus aureus 0 0.05 0.00 Gillespie et al., 2002; Deluyker et al., 2005; Oliver et al., 2004b
2 0.15 0.10
5 0.25 0.20
8 0.40 0.35
Environmental streptococci 0 0.30 0.25 Morin et al., 1998; Deluyker et al., 2005; Hoe and Ruegg, 2005; McDougall et al., 2007
2 0.60 0.55
5 0.70 0.65
8 0.80 0.75
CNS 0 0.60 0.55 Oliver et al., 2004b; Hoe and Ruegg, 2005; McDougall et al., 2007; van den Borne et al., 2010
2 0.75 0.70
5 0.80 0.75
8 0.85 0.80
Escherichia coli 0 0.80 0.75 Wilson et al., 1999; McDougall et al., 2007; Bradley and Green, 2009;  
van den Borne et al., 2010; Suojala et al., 2010.2 0.90 0.85
5 0.90 0.85
8 0.90 0.85
Klebsiella spp. 0 0.40 0.35 Smith et al., 1985; Pyörälä and Pyörälä, 1998; Roberson et al., 2004; Hoe and Ruegg, 2005
2 0.50 0.45
5 0.50 0.45
8 0.50 0.45
No growth 0 0.95 0.90 Roberson et al., 2004; Pinzón-Sánchez, 2010.
2 0.95 0.90
5 0.95 0.90
8 0.95 0.90
ied period was $3,191 and $3,692 for primiparous and 
multiparous cows, respectively. Farm labor was valued 
at $13.00/h (Table 4). No costs were included for vet-
erinary labor because treatments of mild and moderate 
cases of CM are routinely performed by farm personnel 
rather than veterinarians.
Milk Production Losses Due To CM. After oc-
currence of CM and for the remainder of the lactation, 
pathogen-specific milk production losses were estimated 
for primiparous and multiparous cows based on Gröhn 
et al. (2004). Because milk losses were estimated by 
pathogen, weighted averages of milk yield losses were 
calculated for gram-positive and gram-negative patho-
gens, based on the modeled distribution of pathogens 
(Table 5). For primiparous cows, estimated milk losses 
from 30 to 305 DIM were 288 kg (gram-positive), 823 
kg (gram-negative) and 1,017 kg (no growth) (Table 5). 
For multiparous cows, estimated milk losses from 30 to 
305 DIM were 325 kg (gram-positive), 427 kg (gram-
negative), and 166 kg (no growth) (Table 5).
Discarded Milk. To avoid double counting milk 
losses, corrected daily milk production was calculated. 
Daily milk losses due to CM by etiology were sub-
tracted from potential daily milk production to obtain 
the corrected daily milk production. Daily corrected 
milk production was the amount of milk assumed to 
be discarded. When IMM antimicrobials were used, 
days of discarded milk were calculated as duration 
of the treatment plus withholding period (3 d). For 
cows not treated with IMM antimicrobials, losses due 
to discarded milk were assumed for 4 d (Lago, 2009; 
Pinzón-Sánchez, 2010). Days of discarded milk ranged 
from 4 to 11 d. Cost associated with days of discarded 
milk varied by duration of treatment, etiology category 
and DIM.
Milk Production Losses Due To Subclinical 
Mastitis. When cows experienced bacteriological cure, 
no additional losses attributable to subclinical mastitis 
were assumed. When cows did not experience bacte-
riological cure, milk loss was estimated to be 0.4 kg/d 
(primiparous) or 0.6 kg/d (multiparous) for every dou-
bling of SCC >50,000 cells/mL (Seegers et al., 2003). 
The SCC of cows that did not experience bacteriologi-
cal cure was assumed to be 800,000 cells/mL (Pinzón-
Journal of Dairy Science Vol. 94 No. 4, 2011
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Table 3. Weighted average of bacteriological cure for gram-positive, gram-negative, and no growth, based on 
distribution of pathogens used in the baseline (scenario A) 
Etiology of  
clinical mastitis
Treatment  
duration (d)
Bacteriological cure (%)
Primiparous Multiparous
Gram-positive1 0 0.41 0.36
 2 0.63 0.58
 5 0.71 0.66
 8 0.80 0.75
Gram-negative2 0 0.72 0.67
 2 0.82 0.77
 5 0.82 0.77
 8 0.82 0.77
No growth 0 0.95 0.90
 2 0.95 0.90
 5 0.95 0.90
 8 0.95 0.90
1Included Staphylococcus aureus, environmental streptococci, and CNS.
2Included Escherichia coli and Klebsiella spp.
Table 4. Description of assumed costs (baseline) and minimum and maximum scenarios for the initial 
diagnostic or treatment decision 
Description of costs Baseline $ Minimum $ Maximum $
Milk price per kilogram 0.33 0.22 0.44
Farm labor per hour 13.00 8.00 18.00
Intramammary antimicrobial per tube 3.50 2.50 4.50
Total cost of intramammary treatment per day1 6.75 4.50 9.00
Culture plates 2.25 1.25 3.25
Disposable material2 0.50 0.50 0.50
Total cost of on-farm culture per culture3 6.00 3.75 8.25
1Includes 1 intramammary antimicrobial tube and labor (15 min); does not include discarded milk.
2Cost of disposable material was not changed for minimum and maximum scenarios.
3Includes microbiological media, disposable materials, and labor (15 min).
Sánchez, 2010), so milk production was decreased by 
1.6 and 2.4 kg/cow per day for primiparous and mul-
tiparous cows, respectively. For CM caused by gram-
positive bacteria, milk production losses were assumed 
to persist for the remainder of the lactation, whereas 
for CM caused by gram-negative bacteria or when no 
pathogen was recovered (no growth), milk production 
losses occurred for only 2 mo after occurrence of the 
case (de Haas et al., 2004). To avoid double counting 
milk loss, the reduction in milk production began after 
the end of the milk withholding period. For primipa-
rous cows that did not experience bacteriological cure, 
the average cost of milk loss due subclinical mastitis 
was $141.47 (gram-positive), $27.85 (gram-negative), 
and $27.85 (no growth) (Table 6). For multiparous 
cows that did not experience bacteriological cure, the 
average cost of milk loss due subclinical mastitis was 
$212.06 (gram-positive), $41.78 (gram-negative), and 
$41.78 (no growth) (Table 6). Because no additive ef-
fect is known, losses due to subclinical mastitis were 
assumed only for the first case of CM (no additional 
losses were assessed for recurrent cases).
Cost of Diagnosis and Initial Treatment. The 
cost of performing OFC was estimated to be $6.00 and 
included microbiological media ($2.25), disposable ma-
terials ($0.50) such as swabs and gloves, and 15 min of 
labor ($3.25) (Table 4). The fixed cost of purchasing 
an incubator was not included in cost of OFC because 
it was assumed that the OFC program was already es-
tablished on the farm. Initial costs for OFCW included 
cost of OFC and 1 d of discarded milk, and were $14.95 
and $18.85 for primiparous and multiparous cows, 
respectively. Initial costs for OFCT included cost of 
OFC, 1 d of discarded milk, and 1 d of IMM treat-
ment and were $21.70 and $25.60 for primiparous and 
multiparous cows, respectively. Initial cost for NOOFC 
included only the cost associated with 1 d of discarded 
milk and was $8.95 and $12.85 for primiparous and 
multiparous cows, respectively.
Additional Treatment Costs. After the first day, 
the cost of each additional day of IMM treatment 
was assumed as $6.75 and included 1 antimicrobial 
tube ($3.50) and 15 min of labor ($3.25) (Table 4). 
The total additional cost of each treatment strategy 
(beyond the first day) was calculated by adding the 
cost of each treatment strategy and the cost of milk 
discarded. The additional cost of not treating the cow 
with antimicrobials (or stopping the treatment after 
obtaining a pathogen diagnosis) ranged from $25.39 to 
$29.36 for primiparous cows and from $32.89 to $42.13 
for multiparous cows (Table 7). The additional cost of 
treating the cow with antimicrobials for 2 d ranged 
from $40.60 to $62.43 for primiparous cows and from 
$50.60 to $83.71 for multiparous cows (Table 7). The 
additional cost of treating the cow with antimicrobials 
for 5 d ranged from $86.79 to $113.32 for primiparous 
cows and from $104.01 to 146.92 for multiparous cows 
(Table 7). The additional cost of treating the cow with 
antimicrobials for 8 d ranged from $133.96 to $166.41 
for primiparous cows and from $164.70 to $212.02 for 
multiparous cows (Table 7). For OFCW and OFCT, 
pathogen-specific costs of discarded milk were estimated 
using Gröhn et al. (2004). For NOOFC, the additional 
cost of milk discard was based on a weighted average 
depending on the distribution of pathogens included in 
each scenario.
Cost of Transmission of Staph. aureus. Cows 
infected with Staph. aureus that did not experience 
bacteriological cure were assumed to remain subclini-
cally infected, and the potential transmission of conta-
gious pathogens to herdmates was estimated. Similar 
to Swinkels et al. (2005b), non-bacteriologically-cured 
cows were assumed to remain infected for the remain-
der of the lactation (275 d), and each infected cow was 
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Table 5. Estimated effects of the first occurrence of pathogen-specific clinical mastitis on milk yield (kg) from 
30 to 305 DIM by etiology of clinical mastitis under baseline pathogen prevalence using data from Gröhn et 
al. (2004) 
Etiology of  
clinical mastitis
Difference in milk yield1 (kg)
Primiparous cows Multiparous cows
Gram-positive2 −288.42  −325.21
 Staphylococcus aureus −718.43  −558.53
 Environmental streptococci 90.30  −596.80
 CNS −740.96  76.72
Gram-negative2 −823.11  −427.36
 Escherichia coli −670.09  −356.38
 Klebsiella spp. −1,435.19  −711.29
No growth −1,016.78  −166.12
1Positive values indicate milk gain.
2Weighted average based on baseline pathogen distribution.
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Table 6. Estimated cost of production loss ($) due to subclinical mastitis when cows did not experience bacteriological cure1 
Treatment
Cost of production losses due to subclinical mastitis ($)
Primiparous Multiparous
Gram-positive2
Gram-negative 
or no growth3 Gram-positive2
Gram-negative 
or no growth3
On-farm culture wait 24 h,  
 base treatment on diagnostic result
 Do not treat, discard 3 d 143.09 29.57 214.63 44.35
 Treat 2 d, discard 5 d 142.03 28.51 213.05 42.77
 Treat 5 d, discard 8 d 140.45 26.93 210.67 40.39
 Treat 8 d, discard 11 d 138.86 25.34 208.30 38.02
On-farm culture treat immediately,  
 readjust therapy after diagnosis
 Stop treat, discard 3 d 143.09 29.57 214.63 44.35
 Continue 1 d, discard 4 d 142.56 29.04 213.84 43.56
 Continue 4 d, discard 7 d 140.98 27.46 211.46 41.18
 Continue 7 d, discard 10 d 139.39 25.87 209.09 38.81
No use of on-farm culture
 Do not treat, discard 3 d 143.09 29.57 214.63 44.35
 Treat 2 d, discard 4 d 142.56 29.04 213.84 43.56
 Treat 5 d, discard 7 d 140.98 27.46 211.46 41.18
 Treat 8 d, discard 10 d 139.39 25.87 209.09 38.81
 
Average milk loss cost 141.47 27.85 212.06 41.78
1SCC was assumed to be 800,000 cells/mL and milk production was assumed to decrease by 1.6 and 2.4 kg/cow per day for primiparous and 
multiparous cows, respectively (Seegers et al., 2003).
2For clinical mastitis caused by gram-positive bacteria, milk production losses were assumed to persist for the remainder of the lactation.
3For clinical mastitis caused by gram-negative bacteria or when no pathogen was recovered (no growth), milk production losses occurred for only 
2 mo after occurrence of the case (de Haas et al., 2004).
Table 7. Additional partial cost ($) of treating a clinical mastitis case including labor, intramammary antimicrobial treatment, and discarded 
milk (costs from the first day were allocated to diagnosis and initial treatment costs) 
Treatment program1
Partial cost of mastitis treatment ($)
Primiparous Multiparous
Gram-
positive
Gram-
negative
No  
growth Gram-positive Gram-negative
No  
growth
On-farm culture wait 24 h,  
 base treatment on diagnostic result
 Do not treat, discard 3 d 29.36 25.68 25.39 42.13 32.89 39.79
 Treat 2 d 62.43 56.29 55.82 83.71 68.31 79.82
 Treat 5 d 113.32 103.75 102.32 146.92 123.55 140.75
 Treat 8 d 166.41 154.11 149.75 212.02 184.48 203.71
       
On-farm culture treat immediately,  
 readjust therapy after diagnosis
 
 Stop treat, discard 3 d 29.36 25.68 25.39 42.13 32.89 39.79
 Continue 1 d 45.89 40.98 40.60 62.92 50.60 59.81
 Continue 4 d 96.04 87.46 86.79 125.57 104.01 120.13
 Continue 7 d 148.87 137.56 133.96 190.42 164.70 182.84
No use of on-farm culture Weighted average
2 Weighted average2
 Do not treat, discard 3 d  26.86  38.54  
 Treat 2 d  49.32  64.88  
 Treat 5 d  96.98  123.95  
 Treat 8 d  147.01  186.80  
1For all treatment programs, costs for 3-d milk discard are added when animals receive antimicrobials.
2Pathogen-specific milk yield loss weighted by the distribution of pathogens.
assumed to infect 0.25 additional cows. To calculate 
the cost of transmission, the cost of a treating a CM 
case for a standard 5-d treatment was multiplied by 
0.25 and by the prevalence of Staph. aureus. The cost 
of transmission was then added to the total cost of 
recurrence.
Cost of Premature Culling. The cost of premature 
culling was based on Dorshorst et al. (2006). It was as-
sumed that the culled animal was immediately replaced 
by a pregnant heifer with the same production level as 
the culled animal. The cost of a pregnant replacement 
heifer was $1,500. The probability that the replacement 
heifer delivered a female calf was 47%. The value of a 
male calf was $50 versus $250 for a female calf. Thus 
the weighted average value of a calf was $144. The esti-
mated salvage value of a culled cow was $600. The total 
cost of culling (TCC) was calculated by subtracting the 
estimated salvage value and the value of the calf from 
the value of the replacement heifer (i.e., $1,500 – $144 
– $600 = $756). Discounting was used to calculate the 
cost of culling relative to the expected productive life of 
a cow. The assumed culling rate in the herd was 30%. 
The expected number of months for a cow in the herd 
was calculated as 1 divided by cull rate, and multiplied 
by 12. Thus, the expected life (ELM) of a cow was 40 
mo. Using a monthly interest rate (IR) of 0.05% (5% 
annual discount rate), the monthly cost of voluntary 
culling was estimated using the following equation:
 Monthly cost of culling TCC
IR
IR
ELM
= − +( )
−
1 1
.  
The monthly cost of culling was $20.90; this value 
was charged to the month of early culling. For example, 
if a primiparous cow was culled at 60 DIM (2 mo in 
milk), 38 mo would be considered lost, resulting in pre-
mature culling cost of $794 (38 × $20.90). The prema-
ture cost of culling a multiparous cow was assumed for 
a second parity cow. The average calving interval was 
assumed to be 14 mo. For example, if a multiparous 
cow was culled at 90 DIM (3 mo in milk), 23 mo would 
be considered lost (i.e., 40 – 14 – 3 = 23), resulting in 
premature cost of culling of $480.70. In summary, the 
cost of culling was calculated by the difference in the 
value of replacement heifer by the value of salvage and 
offspring, discounted by month of early culling. The 
cost of culling was then the prorated monthly value 
multiplied by the number of months of early culling. 
For primiparous cows, the cost of premature culling 
was $794.20 and $773.30 for animals culled at 60 and 
90 DIM, respectively. For multiparous cows, the cost of 
premature culling was $501.60 and $480.70 for animals 
culled at 60 and 90 DIM, respectively.
Cost of Losing a Mammary Gland Quarter. It 
was assumed that 10% of cows experiencing a recurrent 
case resulted in drying off of the infected mammary 
gland and a subsequent 15% decrease in milk yield for 
the remainder of the lactation. Milk production loss 
due to drying off the chronically infected mammary 
gland was adjusted by DIM.
Costs Due To Recurrence of Mastitis. The costs 
due to recurrent cases included the total cost of 5-d 
IMM treatment, potential loss of a mammary gland 
quarter, and potential transmission (for cases caused by 
Staph. aureus). For primiparous cows, assuming that for 
the first recurrence 95% of the cases were treated and 
5% were culled, the average cost of the first recurrence 
was $192.22. For multiparous cows, assuming that for 
the first recurrence 90% of the cases were treated and 
10% were culled, the average cost of the first recurrence 
was $231.91. For primiparous cows, assuming that for 
the second recurrence 10% of the cases were treated 
and 90% were culled, the average cost of the second 
recurrence was $44.86. For multiparous cows, assuming 
that for the second recurrence 5% of the cases were 
treated and 95% were culled, the average cost of the 
second recurrence was $74.75.
Analysis of Model Outcomes
Economic Losses. The decision tree had 144 termi-
nal values that represented the sum of the partial cash 
flow (total costs) of each possible outcome. The pro-
portional effect of CM on milk income was estimated 
by dividing each terminal value by the estimated total 
milk income that would have been generated if the cow 
did not experience CM.
Expected Monetary Values. The economically 
optimal path in the decision tree was calculated by 
comparison of expected monetary values (EMV). Ex-
pected monetary values were calculated using a process 
of “averaging out and folding back” and were the sums 
of the products of the monetary value of each outcome 
and the probability of that outcome occurring. The op-
timal treatment strategy was the option with the least 
negative EMV (i.e., minimum losses). In this model, 
EMV are negative and represent decrease in milk in-
come; thus, an EMV of −$5 would be more optimal 
than −$10.
Sensitivity Analyses. Sensitivity analyses were 
performed using the minimum and maximum values 
of milk price, cost of farm labor, cost of antimicrobi-
als, and cost of OFC under the baseline prevalence 
(scenario A; Table 4). Additional sensitivity analyses 
were performed by creating 2 additional scenarios 
with differing pathogen distributions. Scenario B was 
characterized by a greater prevalence of CM caused by 
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contagious pathogens (Staph. aureus), and scenario C 
was characterized by a greater prevalence of CM caused 
by coliforms (Table 1).
RESULTS
Economic Losses
Four situations were possible after treatment: (1) cow 
experienced bacteriological cure and CM did not recur, 
(2) cow experienced bacteriological cure but the CM 
did recur, (3) cow did not experience bacteriological 
cure and CM did not recur, or (4) cow did not ex-
perience bacteriological cure but the CM did recur. 
Proportionally, the least economic losses were observed 
for cows that experienced bacteriological cure and did 
not have recurrent cases of CM (best-case scenario) for 
primiparous cows (4–15% of potential milk income was 
decreased) and for multiparous cows (3–9% of potential 
milk income was decreased) (Table 8). The greatest 
proportion of losses was observed for cows that did 
not experience bacteriological cure and had recurrent 
cases of CM (worst-case scenario) for primiparous cows 
(17–23% of potential milk income was decreased) and 
multiparous cows (12–23% of potential milk income was 
decreased) (Table 8). The greatest difference between 
the best and worst case scenario was for CM caused 
by gram-positive pathogens (13–15%) compared with 
CM caused by gram-negative pathogens and no growth 
(7–9%) (Table 8).
EMV for Scenario A  
(Baseline Distribution of Pathogens)
For primiparous cows, the least negative overall 
EMV was for NOOFC (−$323.10), but the differences 
in overall EMV from the other 2 strategies were less 
than $2.26 per case of CM (Table 9). For multiparous 
cows, the least negative overall EMV was for OFCT 
(−$263.79) but the differences with the EMV from the 
other 2 strategies were less than $2.83 per case of CM 
(Table 9).
When the OFCW system was used and the etiology 
of CM was gram-positive, the treatment strategy with 
the least negative EMV was 2DT for primiparous cows 
(−$251.32) and multiparous cows (−$366.97) (Table 9). 
When the etiology of CM was gram-negative, the treat-
ment strategy with the least negative EMV was NOT 
for both primiparous cows (−$340.12) and multiparous 
cows (−$266.35) cows (Table 9). Similarly, when the 
etiology of CM was no growth, the treatment strategy 
with the least negative EMV was NOT for primiparous 
cows (−$383.80) and multiparous cows (−$159.60) 
cows (Table 9).
When the OFCT system was used and the etiology 
of CM was gram-positive, the treatment strategy with 
the least negative EMV was C1DT for primiparous 
cows (−$241.73) and multiparous cows (−$353.25) 
cows (Table 9). When the etiology of CM was gram-
negative, the treatment strategy with the least nega-
tive EMV was STOP for primiparous cows (−$346.87) 
and multiparous cows (−$273.10) (Table 9). Similarly, 
when the etiology of CM was no growth, the treatment 
strategy with the least negative EMV was STOP for 
primiparous cows (−$390.55) and multiparous cows 
(−$166.35) (Table 9).
When the NOOFC system was used, the etiology of 
CM was unknown, and the treatment strategy with the 
least negative EMV was NOT for primiparous cows 
(−$323.10) and 2DT for multiparous cows (−$266.62) 
(Table 9). For primiparous cows the EMV for the 
strategy 2DT was only $3.65 greater than the EMV 
for NOT.
For all OFC systems and all etiologies, a large dif-
ference was observed in EMV of extended treatments 
(5DT, 8DT, C4DT, and C7DT) compared with the least 
negative EMV (Table 9). For primiparous and multipa-
rous cows the difference in EMV ranged from $33.50 
to $163.28 greater for extended treatments (Table 9). 
When OFCW and OFCT were used, the greatest dif-
ference was observed for treating gram-negative and no 
growth for 8 d compared with not treating (Table 9).
EMV for Scenario B  
(Greater Prevalence of Staph. aureus)
For primiparous cows, the least negative overall EMV 
was for NOOFC (−$361.44) and the differences with 
the EMV from the other 2 strategies were less than 
$6.66 per case of CM (Table 9). For multiparous cows, 
the least overall EMV was for NOOFC (−$420.57), and 
the differences with the EMV from the other 2 strate-
gies were less than $9.09 per case of CM (Table 9).
When the OFCW system was used and the etiology 
of CM was gram-positive, the treatment strategy with 
the least negative EMV was 2DT for primiparous cows 
(−$362.53) and multiparous cows (−$517.49) (Table 
9). When the etiology of CM was gram-negative, the 
treatment strategy with the least negative EMV was 
NOT for primiparous cows (−$378.58) and multiparous 
cows (−$289.61) (Table 9). Similarly, when the etiol-
ogy of CM was no growth, the treatment strategy with 
the least negative EMV was NOT for primiparous cows 
(−$383.80) and multiparous cows (−$159.60) (Table 
9).
When the OFCT system was used, and the etiology of 
CM was gram-positive, the treatment strategy with the 
least negative EMV was C1DT for primiparous cows 
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(−$354.00) and multiparous cows (−$504.59) (Table 
9). When the etiology of CM was gram-negative, the 
treatment strategy with the least negative EMV was 
STOP for primiparous cows (−$385.33) and multipa-
rous cows (−$296.36) (Table 9). Similarly, when the 
etiology of CM was no growth, the treatment strategy 
with the least negative EMV was STOP for primipa-
rous cows (−$390.35) and multiparous cows (−$166.57) 
(Table 9).
When the NOOFC system was used, the etiology of 
CM was unknown, and the treatment strategy with 
the least negative EMV was 2DT for primiparous 
cows (−$361.44) and multiparous cows (−$420.57) 
(Table 9).
For all OFC systems and all etiologies, a large dif-
ference was observed for EMV of extended treatments 
(5DT, 8DT, C4DT, and C7DT) compared with the 
least negative EMV (Table 9). For primiparous cows 
the difference ranges from $26.58 to $124.15 greater for 
extended treatments (Table 9). The largest difference 
was observed for treating no growth for 8 d when using 
OFCW system (EMV = −$507.75) (Table 9).
EMV for Scenario C  
(Greater Prevalence of Coliforms)
For primiparous cows, the least negative overall EMV 
was for NOOFC (−$313.89) and the differences with 
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Table 8. Percentage of milk income lost due to clinical mastitis for remainder of lactation (30–305 DIM) relative to potential income of $3,191 
(primiparous cows) and $3,692 (multiparous cows) 
On-farm  
culture  
system Etiology
Treatment  
strategy
Primiparous cows (%) Multiparous cows (%)
Bact. cure No bact. cure Bact. cure No bact. cure
No recur Recur No recur Recur No recur Recur No recur Recur
OFCW1 Gram-positive Do not treat 4.4 8.9 12.3 17.0  4.6 10.4 13.1 19.0
 Treat 2 d 5.4 9.9 13.4 18.0  5.7 11.5 14.2 20.1
 Treat 5 d 7.0 11.4 15.0 19.5  7.4 13.1 15.9 21.8
 Treat 8 d 8.7 13.0 16.6 21.1  9.2 14.8 17.7 23.5
 Gram-negative Do not treat 9.8 10.7 17.1 18.0  5.2 6.4 13.4 14.6
 Treat 2 d 10.8 11.6 18.0 18.9  6.2 7.3 14.3 15.5
 Treat 5 d 12.2 13.1 19.5 20.4  7.7 8.8 15.8 16.9
 Treat 8 d 13.8 14.6 21.1 21.9  9.3 10.4 17.5 18.5
 No growth Do not treat 11.8 12.7 18.2 19.1  3.1 4.3 11.0 12.2
 Treat 2 d 12.7 13.6 19.1 20.0  4.2 5.3 12.1 13.2
 Treat 5 d 14.2 15.0 20.6 21.5  5.8 6.9 13.7 14.8
 Treat 8 d 15.7 16.5 22.1 22.9  7.5 8.5 15.4 16.4
OFCT2 Gram-positive Do not treat 4.6 9.1 12.5 17.2  4.7 10.6 13.3 19.2
 Treat 2 d 5.1 9.6 13.1 17.7  5.3 11.1 13.8 19.7
 Treat 5 d 6.7 11.1 14.6 19.2  7.0 12.7 15.5 21.4
  Treat 8 d 8.3 12.7 16.3 20.8  8.8 14.4 17.3 23.1
 Gram-negative Do not treat 10.0 10.9 17.3 18.2  5.4 6.6 13.6 14.8
 Treat 2 d 10.5 11.4 17.8 18.7  5.9 7.1 14.0 15.2
 Treat 5 d 11.9 12.8 19.2 20.1  7.3 8.5 15.5 16.6
 Treat 8 d 13.5 14.3 20.8 21.6  9.0 10.0 17.1 18.2
 No growth Do not treat 12.0 12.9 18.4 19.3  3.3 4.5 11.2 12.4
 Treat 2 d 12.5 13.4 18.9 19.8  3.8 5.0 11.7 12.9
 Treat 5 d 13.9 14.8 20.3 21.2  5.4 6.6 13.3 14.5
 Treat 8 d 15.4 16.2 21.8 22.6  7.1 8.2 15.0 16.1
NOOFC3 Gram-positive Do not treat 4.1 8.6 12.1 16.7  4.3 10.1 12.8 18.8
 Treat 2 d 4.8 9.3 12.8 17.4  5.0 10.8 13.5 19.5
 Treat 5 d 6.3 10.7 14.3 18.8  6.6 12.3 15.1 21.0
 Treat 8 d 7.9 12.2 15.8 20.3  8.3 14.0 16.8 22.6
 Gram-negative Do not treat 9.6 10.6 16.9 17.8  5.2 6.4 13.4 14.6
 Treat 2 d 10.3 11.3 17.6 18.5  5.9 7.1 14.1 15.3
 Treat 5 d 11.8 12.7 19.1 20.0  7.5 8.6 15.7 16.8
 Treat 8 d 13.4 14.2 20.7 21.5  9.2 10.3 17.4 18.4
 No growth Do not treat 11.6 12.6 18.1 19.0  2.9 4.1 10.8 12.0
 Treat 2 d 12.3 13.3 18.8 19.7  3.6 4.8 11.5 12.7
 Treat 5 d 13.8 14.7 20.3 21.1  5.2 6.3 13.1 14.2
 Treat 8 d 15.4 16.2 21.8 22.6  6.9 7.9 14.8 15.8
1Use on-farm culture and wait 24 h for microbiology results to base treatment on diagnosis.
2Use on-farm culture and treat immediately, then after 24 h, the treatment is readjusted based on diagnosis.
3Do not use on-farm culture.
the EMV from the other 2 strategies were less than 
$7.68 per CM case (Table 9). For multiparous cows, the 
least overall EMV was for NOOFC (−$261.28), and the 
differences with the EMV from the other 2 strategies 
were less than $5.11 per CM case (Table 9).
When the OFCW system was used and the etiology 
of CM was gram-positive, the treatment strategy with 
the least negative EMV was 2DT for primiparous cows 
(−$222.40) and multiparous cows (−$401.01) (Table 
9). When the etiology of CM was gram-negative, the 
treatment strategy with the least negative EMV was 
NOT for primiparous cows (−$323.39) and multiparous 
cows (−$255.35) (Table 9). Similarly, when the etiology 
of CM was no growth, the treatment strategy with the 
least negative EMV was NOT for primiparous cows 
(−$383.59) and multiparous cows (−$158.44) (Table 9).
When the OFCT system was used, and the etiology of 
CM was gram-positive, the treatment strategy with the 
least negative EMV was C1DT for primiparous cows 
(−$212.81) and multiparous cows (−$387.56) (Table 
9). When the etiology of CM was gram-negative, the 
treatment strategy with the least negative EMV was 
STOP for primiparous cows (−$330.14) and multipa-
rous cows (−$262.10) (Table 9). Similarly, when the 
etiology of CM was no growth, the treatment strategy 
with the least negative EMV was STOP for primipa-
rous cows (−$390.34) and multiparous cows (−$165.19) 
(Table 9).
When the NOOFC system was used, the etiology of 
CM was unknown, and the treatment strategy with the 
least negative EMV was NOT for primiparous cows 
(−$313.89) and multiparous cows (−$261.28) (Table 
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Table 9. Expected monetary values (EMV) of different treatment strategies for baseline prevalence (scenario A), high prevalence of contagious 
pathogens (scenario B), and high prevalence of coliforms (scenario C)1  
On-farm  
culture  
(OFC) system OFC result Treatment
Primiparous cows ($) Multiparous cows ($)
A B C A B C
OFCW2 Overall EMV3 −324.33 −368.10 −317.27 −264.20 −429.66 −262.67
 Gram-positive Do not treat −264.94 −369.16 −239.86 −392.01 −529.95 −431.76
  Treat 2 d −251.32 −362.53 −222.40 −366.97 −517.49 −401.01
  Treat 5 d −285.65 −389.11 −255.31 −406.42 −549.08 −437.79
  Treat 8 d −321.85 −411.59 −289.98 −447.33 −574.95 −475.95
 Gram-negative Do not treat −340.12 −378.58 −323.39 −266.35 −289.61 −255.35
  Treat 2 d −362.25 −400.41 −345.65 −290.05 −313.41 −279.02
  Treat 5 d −409.42 −447.41 −392.89 −344.75 −368.22 −333.66
  Treat 8 d −459.50 −497.44 −442.99 −405.13 −428.25 −394.20
 No growth Do not treat −383.80 −383.60 −383.59 −159.60 −159.82 −158.44
  Treat 2 d −414.18 −413.98 −413.97 −199.47 −199.69 −198.31
  Treat 5 d −460.60 −460.40 −460.39 −260.16 −260.38 −259.00
  Treat 8 d −507.95 −507.75 −507.74 −322.88 −323.10 −321.72
OFCT4 Overall EMV −325.36 −364.15 −321.57 −263.79 −422.65 −266.39
 Gram-positive Stop treat −271.69 −375.91 −246.61 −398.76 −536.70 −438.51
  Continue 1 d −241.73 −354.00 −212.81 −353.25 −504.59 −387.56
  Continue 4 d −275.27 −379.99 −244.94 −392.08 −535.45 −423.71
  Continue 7 d −311.17 −402.15 −279.31 −432.68 −560.98 −461.55
 Gram-negative Stop treat −346.87 −385.33 −330.14 −273.10 −296.36 −262.10
  Continue 1 d −353.79 −392.02 −337.16 −279.27 −302.53 −268.28
  Continue 4 d −399.97 −437.99 −383.44 −332.14 −355.68 −321.02
  Continue 7 d −449.80 −487.77 −433.28 −392.28 −415.46 −381.32
 No growth Stop treat −390.55 −390.35 −390.34 −166.35 −166.57 −165.19
  Continue 1 d −405.74 −405.54 −405.53 −186.28 −186.50 −185.13
  Continue 4 d −451.85 −451.65 −451.64 −246.37 −246.59 −245.21
  Continue 7 d −498.94 −498.74 −498.73 −308.84 −309.06 −307.69
NOOFC5 Overall EMV −323.10 −361.44 −313.89 −266.62 −420.57 −261.28
  Do not treat −323.10 −366.74 −313.89 −266.97 −432.38 −261.28
  Treat 2 d −326.75 −361.44 −322.76 −266.62 −420.57 −267.70
  Treat 5 d −368.48 −393.44 −366.89 −317.10 −459.16 −319.05
  Treat 8 d −412.48 −423.48 −414.00 −371.22 −495.36 −376.31
1Least negative EMV is shown in bold.
2Use OFC and wait 24 h for microbiology results to base treatment on diagnosis.
3Overall EMV = expected monetary value for decision 1 (use of OFC system).
4Use OFC and treat immediately, then after 24 h, the treatment is readjusted based on diagnosis.
5Do not use OFC.
9). However, for primiparous cows, the strategy 2DT 
had only $3.65 difference with the NOT strategy.
For all OFC systems and all etiologies, a large dif-
ference was observed for EMV of extended treatments 
(5DT, 8DT, C4DT, and C7DT) compared with the 
least negative EMV (Table 9). For primiparous cows 
the difference ranges from $32.91 to $124.15 greater for 
extended treatments (Table 9). The largest difference 
was observed for treating no growth for 8 d when using 
OFCW system (EMV = −$507.75) (Table 9).
Sensitivity Analysis
For both primiparous and multiparous cows, milk 
price had the greatest effect on the model cost of drug 
or cost of OFC, because minimal differences in EMV 
were observed for the extremes of the other variables 
when compared with EMV from the baseline scenario 
(Tables 10 and 11).
For primiparous and multiparous cows, the treatment 
strategies with the least negative EMV were consis-
tently 2DT or C1DT for gram-positives, and NOT or 
STOP for gram-negatives and no growth, regardless of 
pathogen distribution.
For primiparous cows when NOOFC system was 
used, the least negative EMV was NOT (do not treat) 
regardless of variation in milk price, labor cost, cost of 
drug, or cost of OFC (Table 10). For multiparous cows 
when NOOFC system was used, the treatment strategy 
with the least negative EMV was 2DT except when the 
labor or drug costs were the maximum or milk price 
was the minimum value. In these situations, the least 
negative EMV was NOT (Table 11).
DISCUSSION
As farms increase in size, the herd-level economic im-
pact of treatment decisions often becomes more relevant 
to farm managers compared with decision making for 
individual cows on smaller farms. Decision tree analysis 
is an approach to decision making based on combin-
ing scientific knowledge with economic considerations. 
Rather than simply evaluating clinical or bacteriologi-
cal cure rates, the use of decision tree analysis at the 
cow level allowed the comparison of the economic effect 
of a variety of mastitis treatment strategies that are 
commonly used by dairy farmers in Wisconsin. The 
model is an attempt to define the economically optimal 
treatment strategy for generic treatment of CM while 
evaluating the benefits and cost of treatment. Although 
the use of OFC systems was included in this study, 
the objective was not to determine if use of OFC was 
economically optimal but to determine the most eco-
nomically efficient treatment strategy under a variety 
of potential management situations. The tree included 
best possible assumptions of the costs and biological 
outcomes based on published field trial data and in 
some cases where reliable data was not available as-
sumptions were based on conservative estimates of the 
authors. The decisions used in the tree were ordered to 
reflect the sequence of decisions made by dairy produc-
ers.
Clinical mastitis is a complex disease that involves 
different biological factors. Factors related to the cow 
such as parity, stage of lactation, number of mammary 
gland quarters infected, and previous history of clini-
cal and subclinical mastitis are known to associated 
with treatment outcomes (Sol et al., 2000; Constable 
and Morin, 2003; Deluyker et al., 2005; Bradley and 
Green, 2009; Pinzón-Sánchez, 2010). The analysis was 
done separately for primiparous and multiparous cows 
because of the different shapes of their lactation curves 
and because parity is an important factor that is usu-
ally considered when making treatment decisions. The 
characteristics of the hypothetical cow were typical 
of cows that experience mild and moderate cases of 
clinical mastitis that are expected to result in relatively 
successful posttreatment outcomes. The modeled cow 
was relatively early in lactation with a single mam-
mary gland quarter affected and without previous cases 
of CM. Cows that were experiencing severe cases of 
mastitis, were in very early or late stages of lactation, 
were affected with concurrent disease, or were affected 
with pathogens that are isolated only infrequently from 
cases of CM were not included in this model.
Most mastitis research has focused on outcomes of 
treatment of mastitis caused by contagious pathogens 
such as Staph. aureus. However, many modern dairy 
farms have successfully controlled mastitis caused by 
contagious pathogens, and the distribution of patho-
gens causing mastitis is often dominated by environ-
mental pathogens (Makovec and Ruegg, 2003; Milne 
et al., 2005; Pinzón-Sánchez, 2010). Additionally, 20 
to 40% of CM cases have been reported to yield no 
growth (Roberson et al., 2004; Hoe and Ruegg, 2005; 
Lago, 2009), probably because the cow’s immune sys-
tem has successfully eliminated the infection (Smith 
et al., 1985; Sears et al., 1993). The distribution of 
pathogens modeled in this study was typical of modern 
US dairy farms. The greater diversity of mastitis patho-
gens occurring on modern dairy farms has resulted in 
many farms adopting the use of OFC systems to bet-
ter target treatments for specific diagnoses (Neeser et 
al., 2006). In some instances, (such as recovery of no 
pathogens from CM cases) antimicrobial treatments 
are not administered and in other instances the dura-
tion of treatment may be varied based on diagnosis. 
Most dairy farms that use OFC limit their diagnoses 
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Table 10. Results of sensitivity analysis for primiparous cows1 
On-farm  
culture  
(OFC) system Etiology
Treatment  
strategy Baseline
Milk price/kg ($) Labor cost/h ($) Cost of drug ($) OFC cost ($)
0.22 0.44 8.00 18.00 2.50 4.50 1.25 3.25
OFCW2  Overall EMV3 −324.33 −222.65 −426.01 −321.77 −326.89 −323.28 −325.38 −323.33 −325.33
 Gram-positive Do not treat −264.94 −185.36 −344.52 −262.75 −267.13 −264.19 −265.69 −263.94 −265.94
  Treat 2 d −251.32 −178.52 −324.13 −246.95 −255.70 −248.82 −253.83 −250.32 −252.32
  Treat 5 d −285.65 −207.36 −363.93 −277.63 −293.66 −280.23 −291.06 −284.65 −286.65
  Treat 8 d −321.85 −237.43 −406.26 −310.19 −333.50 −313.52 −330.17 −320.85 −322.85
 Gram-negative Do not treat −340.12 −231.91 −448.32 −338.36 −341.87 −339.71 −340.52 −339.12 −341.12
  Treat 2 d −362.25 −250.30 −474.20 −358.13 −366.37 −359.96 −364.54 −361.25 −363.25
  Treat 5 d −409.42 −288.50 −530.34 −401.55 −417.29 −404.12 −414.71 −408.42 −410.42
  Treat 8 d −459.50 −328.64 −590.36 −447.88 −471.11 −451.20 −467.79 −458.50 −460.50
 No growth Do not treat −383.80 −258.84 −508.77 −382.37 −385.24 −383.65 −383.96 −382.80 −384.80
  Treat 2 d −414.18 −283.59 −544.77 −410.24 −418.12 −412.03 −416.33 −413.18 −415.18
  Treat 5 d −460.60 −321.29 −599.92 −452.92 −468.29 −455.45 −465.75 −459.60 −461.60
  Treat 8 d −507.95 −359.61 −656.29 −496.51 −519.39 −499.80 −516.10 −506.95 −508.95
OFCT4  Overall EMV −325.36 −224.80 −425.92 −321.99 −328.73 −323.66 −327.06 −324.36 −326.36
 Gram-positive Stop treat −271.69 −192.11 −351.27 −268.25 −275.13 −269.94 −273.44 −270.69 −272.69
  Continue 1 d −241.73 −172.13 −311.34 −237.36 −246.11 −239.23 −244.23 −240.73 −242.73
  Continue 4 d −275.27 −200.44 −350.09 −267.25 −283.28 −269.86 −280.68 −274.27 −276.27
  Continue 7 d −311.17 −230.31 −392.03 −299.52 −322.82 −302.85 −319.49 −310.17 −312.17
 Gram-negative Stop treat −346.87 −238.66 −455.07 −343.86 −349.87 −345.46 −348.27 −345.87 −347.87
  Continue 1 d −353.79 −244.66 −462.91 −349.67 −357.90 −351.49 −356.08 −352.79 −354.79
  Continue 4 d −399.97 −282.20 −517.74 −392.11 −407.84 −394.68 −405.27 −398.97 −400.97
  Continue 7 d −449.80 −322.17 −577.42 −438.18 −461.41 −441.50 −458.09 −448.80 −450.80
 No growth Stop treat −390.55 −265.59 −515.52 −387.87 −393.24 −389.40 −391.71 −389.55 −391.55
  Continue 1 d −405.74 −277.97 −533.52 −401.80 −409.68 −403.59 −407.89 −404.74 −406.74
  Continue 4 d −451.85 −315.46 −588.24 −444.16 −459.54 −446.70 −457.00 −450.85 −452.85
  Continue 7 d −498.94 −353.60 −644.28 −487.50 −510.38 −490.79 −507.09 −497.94 −499.94
NOOFC5  Overall EMV −323.10 −219.04 −427.15 −322.55 −323.64 −322.66 −323.53 −323.10 −323.10
  Do not treat −323.10 −219.04 −427.15 −322.55 −323.64 −322.66 −323.53 −323.10 −323.10
  Treat 2 d −326.75 −224.93 −428.57 −323.86 −329.65 −324.44 −329.07 −326.75 −326.75
  Treat 5 d −368.48 −259.23 −477.74 −361.88 −375.09 −363.20 −373.77 −368.48 −368.48
  Treat 8 d −412.48 −295.02 −529.94 −402.16 −422.79 −404.22 −420.73 −412.48 −412.48
1Least negative expected monetary values (EMV) for each are shown in bold.
2Use OFC and wait 24 h for microbiology results to base treatment on diagnosis.
3Overall EMV = expected monetary value for decision 1 (use of OFC system).
4Use OFC and treat immediately, then after 24 h, the treatment is readjusted based on diagnosis.
5Do not use OFC.
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Table 11. Results of sensitivity analysis for multiparous cows1 
On-farm  
culture  
(OFC) system Etiology
Treatment  
strategy Baseline
Milk price/kg ($) Labor cost/h ($) Cost of drug ($) OFC cost ($)
0.22 0.44 8.00 18.00 0.22 0.44 8.00 18.00
OFCW2  Overall EMV3 −264.20 −189.09 −339.32 −261.03 −267.38 −262.67 −265.74 −263.20 −265.20
 Gram-positive Do not treat −392.01 −277.82 −506.20 −389.23 −394.79 −390.79 −393.24 −391.01 −393.01
  Treat 2 d −366.97 −262.79 −471.15 −361.99 −371.95 −363.98 −369.95 −365.97 −367.97
  Treat 5 d −406.42 −294.84 −517.99 −397.79 −415.04 −400.52 −412.32 −405.42 −407.42
  Treat 8 d −447.33 −327.84 −566.82 −435.06 −459.59 −438.52 −456.14 −446.33 −448.33
 Gram-negative Do not treat −266.35 −189.48 −343.22 −263.99 −268.71 −265.46 −267.24 −265.35 −267.35
  Treat 2 d −290.05 −208.62 −371.49 −285.32 −294.78 −287.27 −292.84 −289.05 −291.05
  Treat 5 d −344.75 −251.83 −437.66 −336.26 −353.23 −338.96 −350.53 −343.75 −345.75
  Treat 8 d −405.13 −298.84 −511.42 −392.90 −417.36 −396.35 −413.91 −404.13 −406.13
 No growth Do not treat −159.60 −115.05 −204.15 −157.54 −161.66 −158.95 −160.25 −158.60 −160.60
  Treat 2 d −199.47 −146.13 −252.81 −194.91 −204.03 −196.82 −202.12 −198.47 −200.47
  Treat 5 d −260.16 −193.34 −326.98 −251.85 −268.47 −254.51 −265.81 −259.16 −261.16
  Treat 8 d −322.88 −241.90 −403.85 −310.82 −334.94 −314.23 −331.53 −321.88 −323.88
OFCT4  Overall EMV −263.79 −190.28 −337.31 −259.81 −267.78 −261.60 −265.98 −262.79 −264.79
 Gram-positive Stop treat −398.76 −284.57 −512.95 −394.73 −402.79 −396.54 −400.99 −397.76 −399.76
  Continue 1 d −353.25 −253.65 −452.86 −348.28 −358.23 −350.27 −356.24 −352.25 −354.25
  Continue 4 d −392.08 −285.29 −498.88 −383.46 −400.71 −386.18 −397.98 −391.08 −393.08
  Continue 7 d −432.68 −318.07 −547.29 −420.42 −444.95 −423.87 −441.49 −431.68 −433.68
 Gram-negative Stop treat −273.10 −196.23 −349.97 −269.49 −276.71 −271.21 −274.99 −272.10 −274.10
  Continue 1 d −279.27 −201.43 −357.11 −274.54 −284.00 −276.49 −282.06 −278.27 −280.27
  Continue 4 d −332.14 −243.43 −420.85 −323.66 −340.62 −326.35 −337.92 −331.14 −333.14
  Continue 7 d −392.28 −290.27 −494.29 −380.05 −404.51 −383.49 −401.06 −391.28 −393.28
 No growth Stop treat −166.35 −121.80 −210.90 −163.04 −169.66 −164.70 −168.00 −165.35 −167.35
  Continue 1 d −186.28 −137.34 −235.23 −181.72 −190.84 −183.64 −188.93 −185.28 −187.28
  Continue 4 d −246.37 −184.14 −308.59 −238.06 −254.68 −240.72 −252.01 −245.37 −247.37
  Continue 7 d −308.84 −232.55 −385.14 −296.78 −320.90 −300.19 −317.49 −307.84 −309.84
NOOFC5  Overall EMV −266.62 −188.35 −341.97 −263.11 −268.12 −263.81 −267.89 −266.62 −266.62
  Do not treat −266.97 −188.35 −345.59 −265.82 −268.12 −266.05 −267.89 −266.97 −266.97
  Treat 2 d −266.62 −191.28 −341.97 −263.11 −270.13 −263.81 −269.43 −266.62 −266.62
  Treat 5 d −317.10 −231.33 −402.87 −309.88 −324.32 −311.32 −322.88 −317.10 −317.10
  Treat 8 d −371.22 −273.80 −468.64 −360.28 −382.15 −362.47 −379.96 −371.22 −371.22
1Least negative expected monetary values (EMV) for each option are shown in bold.
2Use OFC and wait 24 h for microbiology results to base treatment on diagnosis.
3Overall EMV = expected monetary value for decision 1 (use of OFC system).
4Use OFC and treat immediately, then after 24 h, the treatment is readjusted based on diagnosis.
5Do not use OFC.
to categories such as gram-positive, gram-negative, or 
no growth; however, the decision tree included the un-
derlying pathogen distribution within these categories 
to estimate bacteriological cure and production losses. 
The inclusion of this distribution enhanced the accu-
racy of the model, taking advantage of recent research 
describing pathogen-specific bacteriological cure and 
milk losses (de Haas et al., 2004; Gröhn et al., 2004; 
Oliver et al., 2004a,b).
Use of OFC programs is a simple and easy technique 
that, when used correctly, allows producers to identify 
the possible pathogen causing CM (Neeser et al., 2006; 
Lago, 2009). Many progressive dairy producers use 
OFC to determine etiology of CM case and develop 
selective treatments accordingly. When OFC is used, 
IMM antimicrobials are often administered to cows 
experiencing CM caused by gram-positive pathogens 
and in some instances IMM antimicrobials are not used 
for CM caused by gram-negative pathogens or when 
no pathogen is isolated (Lago, 2009). At least 2 differ-
ent OFC programs are used by farmers (Neeser et al., 
2006). The first program is to postpone initiation of 
treatment for 24 h until microbiological results from 
OFC are available (OFCW), which has been reported 
not to have adverse effects on outcomes of mild and 
moderate cases of CM (Lago, 2009). The second pro-
gram is to start IMM antimicrobial treatment imme-
diately after detection of CM but to adjust treatment 
based on microbiological results obtained from OFC 
after 24 h of incubation (OFCW). Although OFC is 
often used on larger farms, many farmers have not yet 
implemented the use of OFC and treatment of CM 
cases is done without knowledge of causative pathogen. 
For this reason NOOFC was included in the tree to 
reflect all possible options.
Using the assumptions that were included in this 
model, only small differences in overall EMV were 
observed among all OFC systems (OFCW, OFCT, 
NOOFC; Tables 9 to 11). Greater differences in EMV 
were observed based on duration of treatment and the 
overall differences among OFC systems were primar-
ily a result of the model selecting shorter duration 
treatments (or no treatment) as the optimal economic 
pathway used to calculate overall EMV. In reality, the 
cost saving that occurs when OFC is used is generally 
associated with reduced milk discard due to fewer IMM 
antimicrobial treatments. In this model, those savings 
were not apparent because the model generally recom-
mended no treatment or short-duration therapy. If a 
farm was using short-duration therapy (or no treatment) 
as the primary mastitis treatment strategy, this model 
indicates that OFC is not likely to result in additional 
economic benefits. In contrast, herds that routinely use 
extended-duration therapy without regard for pathogen 
diagnosis could incur considerable savings by adopt-
ing OFC. For example, a 1,000-cow dairy with a 40% 
incidence of CM and a distribution of pathogens similar 
to that in scenario A would experience 400 first cases 
of mastitis per year. If the standard treatment was 5 
d of IMM antimicrobial without regard to diagnosis 
(NOOFC), the EMV (loss) for each case occurring in 
primiparous cows would be approximately $369 (from 
Table 9) or $147,600 per year (for 400 cases). In con-
trast, the overall EMV for each case treated using a 
strategy of OFCW would be $325 or $130,000 per year. 
In this instance, the use of OFC would result in ap-
proximately $18,000 in annual savings.
The treatment strategies used in the model reflect 
the reality of treatments used on many modern dairy 
farms. Varying durations of treatment and the inclusion 
no IMM treatment were based on common practices 
used in the United States. Most IMM antimicrobials 
commercially available in the United States are not 
labeled for treatment of gram-negative pathogens but 
the generic drug used in the model was assumed to 
be effective against both gram-negative and gram-pos-
itive pathogens, allowed for use for extended-duration 
therapy, and required 72 h of milk discard. These 
characteristics are similar to at least one popular IMM 
antimicrobial marketed in the United States.
Although bacteriological cures are not typically as-
sessed on farms, the inclusion of this outcome in the 
model allowed us to estimate the economical conse-
quences of CM. Greater probability of bacteriological 
cure was assumed for primiparous cows as compared 
with multiparous cows because researchers consistently 
report that greater parities are associated with a re-
duced probabilities of cure (Sol et al., 2000; Barkema 
et al., 2006). Several clinical trials have evaluated 
bacteriological cure after treatment of CM using differ-
ent compounds and differing treatment durations. Re-
search data describing bacteriological cure using similar 
antimicrobial compounds was not available for all the 
pathogens and all treatment durations included in the 
model. For this reason, assumptions of bacteriological 
cure were based on a logical combination of relevant 
clinical trials that used different active compounds and 
different durations, and in some instances, were used to 
assess bacteriological cure after treatment of subclinical 
mastitis cases (when data from appropriate studies of 
CM was not available).
With the exception of bacteriologically negative cases 
(no growth), cows receiving IMM antimicrobials were 
assumed to have greater bacteriological cure than cows 
not receiving antimicrobials (Oliver et al., 2004b; van 
den Borne et al., 2010). Most research of extended 
therapy used for treatment of CM described outcomes 
for mastitis caused by gram-positive pathogens (Oliver 
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et al., 2003, 2004a,b; Gillespie et al., 2002). For CM 
caused by gram-positive pathogens, the probability 
of bacteriological cure was assumed to increase with 
increased duration of treatment (Gillespie et al., 2002; 
Oliver et al., 2004b; Deluyker et al., 2005). Most IMM 
antimicrobials commercially available in the United 
States are not labeled for treatment of gram-negative 
pathogens, and for CM caused by gram-negative patho-
gens the probability of bacteriological cure was not 
influenced by treatment duration. Very little research 
has described outcomes for cases of CM that have 
not yielded bacterial growth (Roberson et al., 2004; 
Pinzón-Sánchez, 2010) and bacteriological cure was not 
increased with increased duration of treatment for this 
etiology. Similar or greater proportion of bacteriological 
cure has been reported for CM caused by E. coli treated 
without use of antimicrobials (Guterbock et al., 1993; 
Roberson et al., 2004). The greatest bacteriological cure 
was assumed for cows infected with E. coli (van den 
Borne et al., 2010) and when no pathogen was recov-
ered (Roberson et al., 2004). The least bacteriological 
cure was assumed for cows infected with Staph. aureus 
(Gillespie et al., 2002; Oliver et al., 2004b).
The probability of recurrence have been reported to 
be around 20% (Hoe and Ruegg, 2005; Wenz et al., 
2005; Pinzón-Sánchez, 2010) and is known to vary with 
parity. In this model the overall probability of recur-
rence was estimated as 13 and 23% for primiparous and 
multiparous cows, respectively. Some previous models 
used to estimate economic losses of CM did not assume 
recurrence of CM (Huijps et al., 2008) but this model 
included the potential occurrence of 2 additional cases 
of CM. Cows that did not experience bacteriological 
cure were more likely to experience recurrent cases 
(Wenz et al., 2005; Pinzón-Sánchez, 2010). Almost no 
data were found to estimate the probability of recur-
rence of CM by pathogen, so probability of recurrence 
was assumed equal for all pathogens. However, recur-
rence was driven by the probability of bacteriological 
cure and bacteriological cure was estimated based on 
etiology. The cost of recurrences (treatment, discarded 
milk, potential loss of a mammary gland quarter, and 
potential transmission of contagious pathogens) were 
similar for first and second recurrence. The overall cost 
of recurrence appears to be greater for the first recur-
rence (compared with the second) because the cost of 
the second recurrence is multiplied by a succession of 
probabilities (probabilities of cure, recurrence, and treat-
ment). Some possible effects of mastitis were difficult to 
estimate because the research literature is insufficient. 
For example, no research was available to document 
the potential reduction in milk yield when a mammary 
gland quarter is selectively dried off. Our estimate of 
a 15% decrease in milk yield may be an overestimate. 
However, the effect of this assumption was very small 
because milk yield losses were approximately $40 to $50 
and occurred only in 10% of recurrent cases.
Culling decisions are directly affected by diseases 
(such as clinical mastitis) that result in marked de-
creases in milk production (DeGraves and Fetrow, 1993; 
Gröhn et al., 2005; Hadley et al., 2006). Occurrence of 
previous cases of CM is associated with less probability 
of cure. Some larger US farms have an abundance of 
replacement animals and elect to aggressively cull cows 
that experience recurrent cases of mastitis. Culling 
most cows that experience a third case of CM during 
their current lactation is often referred to as the “three 
strikes and out” rule. This policy was included in this 
model to reflect current management practices.
Information about pathogen-specific losses attribut-
able to CM is sparse and the estimates used in this 
model were the best available to estimate milk loss 
for cases of CM occurring on modern dairy farms. 
Pathogen-specific milk production losses were esti-
mated based on research conducted by Gröhn et al. 
(2004). However, these estimates included CM cases 
of all severities and in various stages of lactation, in 
contrast to the mild and moderate cases occurring at 
30 DIM evaluated in this model. Gröhn et al. (2004) 
reported milk yield losses for cases of treated mastitis 
in absence of reporting bacteriological cure so the effect 
of additional losses caused by subclinical mastitis are 
not differentiated. The largest estimated milk loss was 
for CM caused by Klebsiella spp., with losses of 1,435 
kg for primiparous cows and 711 kg for multiparous 
cows. Estimated milk losses when CM was caused by 
Staph. aureus were 718 and 558 kg for primiparous and 
multiparous cows, respectively. Interestingly, Gröhn et 
al. (2004) reported that primiparous cows affected with 
CM caused by environmental streptococci produced an 
additional 90 kg of milk and multiparous cows affected 
with CM caused by CNS produced an additional 76 kg 
of milk. Although these estimates are unusual and may 
reflect characteristics of the underlying herds included 
in that study, these estimates were used in the decision 
tree model. Based on the data provided by Gröhn et al. 
(2004), milk production losses due to CM were greater 
for primiparous cows than for multiparous cows. The 
primary reason for this outcome was the large dif-
ference (850 kg) in estimated losses for CM cases in 
which no pathogen was recovered. Gröhn et al. (2004) 
reported that primiparous cows affected with CM that 
were diagnosed as no growth resulted in production 
losses of 1,017 kg in contrast to 166 kg of milk yield 
loss for multiparous cows. As explained by Gröhn et al. 
(2004), although losses for multiparous cows became 
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smaller by d 43 after diagnosis, losses for primiparous 
cows remained substantial for the remainder of the 
studied period. Other researchers have suggested that 
CM cases that yield no bacteria have similar charac-
teristics as gram-negative bacterial infections (Morin 
et al., 1998).
Somatic cell counts >200,000 cells/mL are an indi-
cator of subclinical infection and are associated with 
reduced milk production (Hortet and Seegers, 1998). 
The effects of subclinical mastitis were included in the 
calculations for this model for cases of CM that did 
not result in bacteriological cure. The effects of CM on 
lactation curves for SCC differ among pathogens (de 
Haas et al., 2002, 2004). As de Haas et al. (2002, 2004) 
reported that after a case of CM caused by E. coli or 
for culture-negative samples, SCC rapidly decreased. 
However, for cases of CM caused by Staph. aureus or 
environmental streptococci, SCC remained increased 
after the occurrence. Based on this information, 2 mo of 
milk losses due to subclinical mastitis were assumed for 
gram-negative pathogens and no growth results. Losses 
due to subclinical mastitis caused by gram-positive 
pathogens were assumed to persist for the remainder 
of the lactation.
The great economic impact of CM is well known and 
has been described previously (Seegers et al., 2003; 
Halasa et al., 2007; Bar et al., 2008). The largest propor-
tion of economic losses caused by mastitis (reduction of 
milk production) is generally not evident, and economic 
losses are usually underestimated by farmers (Huijps et 
al., 2008). When assessing the direct economic impact 
of mastitis, costs (i.e., extra resource use) and losses 
(i.e., reduced revenues) should be aggregated (Seegers 
et al., 2003). This decision tree model used components 
to calculate economic losses attributable to mastitis 
similar to models developed by Huijps et al. (2008) at 
the farm level and Swinkels et al. (2005a,b) at the cow 
level. Although both of those models were developed 
for typical European conditions, this model is specific 
for US conditions. Inclusion of pathogen-specific esti-
mations to calculate costs of CM is unique and likely 
improves the precision of the estimates of economic 
damage caused by CM compared with previous models. 
Although other studies have reported losses including 
milk loss due to CM, discarded milk, and due to sub-
clinical mastitis (Shim et al., 2004; Huijps et al., 2008), 
this decision tree uniquely includes pathogen-specific 
milk losses. The decision tree included milk production 
losses due to clinical and subclinical mastitis, discarded 
milk, cost of drugs, diagnostic, labor, culling, and recur-
rences; these components are similar to previous studies 
(Seegers et al., 2003; Huijps et al., 2008). Economic 
losses from premiums not received by producer due to 
increased SCC in bulk tank were not included in the 
model because it was difficult to assign a herd-level 
value to an individual cow.
The cost per case of clinical mastitis varies widely 
among studies due to the inclusion of different costs 
and diverse objectives and populations studied. The 
total cost of CM in our model ranged from $106 to $867 
and included costs of drugs, labor, discarded milk, milk 
losses due to clinical and subclinical mastitis, culling, 
and recurrences. For example, a CM case caused by a 
gram-positive pathogen treated for 2 d, and assuming 
that the cow did not experience bacteriological cure 
and recurred, would cost $743 distributed as diagnostic 
costs (2%), milk loss due to CM (14%), treatment cost 
(11%), milk loss due to subclinical mastitis (29%), and 
cost of recurrence (44%). Bar et al. (2008) estimated 
that average cost of a case of CM was $179 distributed 
as follows: drugs (11%), discarded milk (11%), labor 
(5%), milk yield losses (64%), and mortality (7%); how-
ever, cost of recurrence was not included. Rodrigues 
et al. (2005) calculated the partial cost of a case of 
CM for Wisconsin dairy herds participating in a milk 
quality program and reported that the average partial 
cost per case of CM was $91, distributed as discarded 
milk (60%), cost of treatments (21%), and cost of labor 
(19%). To make this data comparable to our model 
and including only the cost included by Rodrigues et 
al. (2005), the partial cost per case of mild and mod-
erate CM in our model ranged from $25 (no IMM 
antimicrobial) to $212 (8-d extended treatment) per 
case depending on the treatment strategy. For example, 
a 2-d treatment when NOOFC was used was $50 per 
case for primiparous cows and included treatment cost 
(27%) and milk discarded (73%), and $60 per case for 
multiparous cows and included treatment cost (20%) 
and milk discarded (80%). It is important to note that 
discarded milk corresponds to the corrected daily milk 
yield used in our model, thus milk losses due to CM 
were already decreased.
Discarded milk usually accounts for a large propor-
tion of economic losses attributable to CM (Seegers et 
al., 2003; Rodrigues et al., 2005; Halasa et al., 2007). 
The assumption of discarding milk for 4 d, when no 
antimicrobial was administered was based on the dura-
tion of days until the disappearance of clinical signs 
previously reported (Hoe and Ruegg, 2005; Lago, 2009; 
Pinzón-Sánchez, 2010). Our model assumed 1 d less of 
discarded milk when a cow was not treated with anti-
microbials (4 d of milk discarded) compared with treat-
ment with antimicrobial for 2d (5 d of milk discarded). 
When CM was caused by a gram-negative pathogen or 
no growth, the best treatment strategy was not to treat 
with antimicrobials. To reduce the loss from discarded 
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milk, the use of a quarter milker is sometimes recom-
mended.
Extended-duration IMM therapy has been shown 
to result in increased bacteriological cures for mastitis 
caused by Staph. aureus and some environmental strep-
tococci but the routine use of extended-duration therapy 
was not economically optimal under any circumstance 
evaluated in this study. Previous researchers have used 
partial budgeting to evaluate the economic effect of 
different treatment strategies for subclinical IMM in-
fection caused by environmental streptococci or Staph. 
aureus (Swinkels et al., 2005a,b). Similar to the results 
reported herein, Swinkels et al. (2005a) concluded that 
extended treatment is not economically feasible because 
of the increased cost of antimicrobials and increased 
losses due to milk discard. The same authors (Swinkels 
et al., 2005b) reported that extended-duration treat-
ment of subclinical mastitis caused by Staph. aureus 
was economically justified only in circumstances when 
the risk of transmission to other cows was great.
When CM is treated without knowledge of etiology, it 
is difficult to justify the routine use of extended-duration 
therapy for treatment of the first case of CM. Although 
the least overall economic loss was typically associated 
with either a no-treatment option or a 2-d course of 
therapy, the differences in EMV between no treatment 
and 2-d treatments were generally very small. Based on 
existing research, bacteriological cure rates were only 
marginally improved by 5 d of therapy relative to 2 d of 
therapy. These small increases (5–10%) in bacteriologi-
cal cure were not sufficient to offset the larger losses 
attributable to more days of discarded milk. In light of 
the limited amount of pathogen-specific research and 
the uncertainty inherent in models, it is not prudent to 
conclude that no treatment is preferred but care should 
be taken to recommend extended-duration therapy 
only in circumstances where etiologies and clinical ex-
perience suggest that a beneficial economic effect will 
result.
Sensitivity analyses were performed to explore the ef-
fect of changes in selected inputs on important model 
outputs and to identify input variables with a strong 
effect on the model outputs. Milk price was the only in-
put variable that influenced the model. When milk price 
was low, the EMV were less negative, indicating that 
the reduction in milk income was less compared with 
the baseline. Similarly, when milk price was high, EMV 
were more negative, indicating that the reduction in 
milk income was greater compared with the baseline.
CONCLUSIONS
A cow-level decision tree was developed to evaluate 
the economic impact of selected mastitis treatment 
strategies. Culture-based therapy allowed for the most 
judicious use of antimicrobials. For most scenarios, the 
results of the model suggested that the best strategy 
was to treat mastitis caused by gram-positive pathogens 
for 2 d and avoid use of antimicrobials for CM caused 
by gram-negative pathogens or when no pathogen was 
recovered. Use of extended therapy (5 or 8 d) resulted 
in the least EMV. Decision tree analysis is an effective 
method for determining the most economically optimal 
treatment strategy for commercial dairy herds and is 
a useful instructional tool to understand the complex 
interactions affecting the economics of treatment of 
CM. The biological assumptions of this model could be 
strengthened by field studies designed to better char-
acterize posttreatment outcomes in dairy cows. Further 
study to extrapolate the model for cows with different 
DIM or with a previous history of clinical and subclini-
cal mastitis is needed.
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